Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreate… (NCT06167421) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy
240 participantsStarted 2024-01-01
Plain-language summary
This study aims to compare the surgical outcomes of laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique versus the Warshaw technique. The primary focus is on the rates of unplanned splenectomy, occurrence of severe complications, as well as intraoperative and perioperative outcomes of both techniques.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 18 and 70 years, regardless of gender.
* Preoperative clinical diagnosis of benign or low-grade malignant pancreatic tumors.
* Meeting the recommended surgical indications as per guidelines.
* Feasibility of imaging assessment for either Kimura or Warshaw technique laparoscopic spleen-preserving distal pancreatectomy.
* Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) score.
* Willingness to comply with the study treatment plan, follow-up schedule, and other protocol requirements.
* Voluntarily participating in the study and signing an informed consent form.
Exclusion Criteria:
* Body Mass Index (BMI) \> 28 kg/m2 (Chinese obesity standard).
* History of blood disorders, acute or chronic pancreatitis, gastrointestinal bleeding, splenic rupture, or gastric varices (preoperative CT indicating curved vessel structures along the gastric wall with a diameter \> 5mm).
* History of abdominal surgery.
* Concomitant primary malignant tumors.
* Suspicion of malignancy based on PET-CT or other imaging examinations.
* Severe impairment of cardiac, liver, or kidney function (NYHA class 3-4, ALT and/or AST exceeding three times the upper limit of normal, Creatinine exceeding the upper limit of normal).
* Planned pregnancy or pregnancy and lactating women.
* Participants currently involved in other clinical trials.